logo
Asian food staple great for heart health — the ‘magic' is actually what's grown on it, expert says

Asian food staple great for heart health — the ‘magic' is actually what's grown on it, expert says

New York Post03-06-2025
Rice, rice, baby.
Not everyone knows that rice is a whole world that extends far beyond the white or brown on offer at your Chinese local.
But there's one particularly healthy variety that has managed to largely fly under the radar on this side of the pond.
3 Red yeast rice — used in traditional Chinese medicine — is known for its benefits for cardiovascular health.
MilletStudio – stock.adobe.com
'Red yeast rice is a brightly colored compound used in food and health products that is made by fermenting rice with a special type of yeast known as Monascus purpureus,' Dr. Amanda Frick, VP Medical Affairs at Thorne, told The Post.
'Red yeast rice has been used in traditional Chinese and western botanical medicine to maintain healthy cholesterol levels and support blood circulation.'
Research has shown this crimson product contains naturally occurring compounds that can help keep total and LDL cholesterol — as well as triglycerides, which are the most common type of fat in the body — at optimal levels.
It also contains a bunch of other, unpronounceable compounds — such as phytosterols beta-sitosterol, campesterol, and stigmasterol, and isoflavones — that can help keep your ticker running smoothly.
But the real secret sauce isn't what's in it so much as on it.
'Red yeast rice does get a lot more attention for its health benefits than your everyday white or brown rice. The 'magic' of red yeast rice isn't actually in the rice itself — it's in what's grown on it,' Frick said.
3 Research has shown this crimson product contains naturally occurring compounds that can help keep total and LDL cholesterol — as well as triglycerides, which are the most common type of fat in the body — at optimal levels.
Syda Productions – stock.adobe.com
'While white and brown rice provide a source of carbohydrates and fiber (depending on the rice type), they do not contain the additional nutrients like sterols and antioxidants that are found in red yeast rice.'
While it is a rice, it's more commonly found in powdered form or as a supplement — or in some fermented foods.
'There are foods like fermented tofu, red rice vinegar, and Japanese rice wine (sake) that include red yeast rice,' Frick said.
'Depending on the specific use in traditional Chinese medicine, it may be best prepared with other food ingredients or at a particular temperature.
'For uses in botanical medicine, it's often preferred to offer in a supplement form for consistent delivery of the bioactive compounds in red yeast rice.'
3 'While white and brown rice provide a source of carbohydrates and fiber (depending on the rice type), they do not contain the additional nutrients like sterols and antioxidants that are found in red yeast rice,' Frick said.
Pixel-Shot – stock.adobe.com
While the side effects tend to be relatively mild — think gas, tummy troubles, headache and reddish poop — red yeast rice isn't for everyone.
'As with any new dietary supplement, it's important to discuss starting red yeast rice with your health professional, who can determine if this is the right option for you, your lifestyle and your overall wellness plan,' she said.
'Women who are trying to become pregnant, pregnant or breastfeeding shouldn't take red yeast rice. Those who have kidney or liver disease also shouldn't take it. Additionally, it may interact with certain medications, supplements, alcohol and grapefruit.'
One other red flag: contamination. Some red yeast rice supplements can contain citrinin — a toxic byproduct of the fermentation process that can damage your kidneys or liver.
Red yeast rice might not be magic — but when it's properly made and thoughtfully used, it could be a powerful addition to your heart-health toolkit.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US Sends Icebreaker to Arctic Amid China Rivalry
US Sends Icebreaker to Arctic Amid China Rivalry

Newsweek

time29 minutes ago

  • Newsweek

US Sends Icebreaker to Arctic Amid China Rivalry

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A Newsweek map shows that both the United States and China have deployed icebreakers to Arctic waters north of Alaska recently, as the two powers jostle for dominance in the region. USCGC Healy—America's largest and most technologically advanced icebreaker—is conducting a mission to reinforce U.S. presence in the Arctic, the U.S. Coast Guard said. Regarding the deployment of the Chinese icebreaker Xue Long 2, the Chinese Embassy in Washington, D.C., told Newsweek that China has always conducted normal maritime activities in accordance with international law. Why It Matters China has claimed the status of a "near-Arctic state" and a stakeholder in Arctic affairs. In recent years, the East Asian power has gradually expanded its Arctic presence, including deploying icebreakers and conducting scientific research with potential military applications. Alarmed by China's activities in the Arctic—which include its cooperation with Russia—the Pentagon has updated its Arctic strategy, calling for a greater military presence, enhanced intelligence capabilities and closer cooperation with allies to address these challenges. What To Know Using open-source data, the Healy was tracked departing Dutch Harbor—a key fishing port on Alaska's Amaknak Island—on July 13. Four days later, it transited the Bering Strait, which separates Alaska from Russia's Far East, during its northbound voyage. A Newsweek map shows that the Xue Long 2—China's first domestically built icebreaker—passed through the waterway a day after the Healy's transit. As of July 26, both vessels were tracked underway in Arctic waters on the U.S. Extended Continental Shelf (ECS)—an area of continental shelf extending beyond 230 miles from America's coastline, where the U.S. has exclusive rights to conserve and manage resources. The Healy was also observed sailing in the Chukchi Sea—north of the Bering Strait—and the Bering Sea on July 5 and July 9, respectively, according to photos released by the U.S. Coast Guard. The vessel departed its home port of Seattle, Washington, on June 19 to conduct what the U.S. Coast Guard described as "high-latitude science and research missions" in the Arctic. In a Facebook post on Monday, the U.S. Coast Guard said the Healy recently began its annual Arctic deployment, aimed at conducting "vital research" on sea ice and ocean movement. The United States Coast Guard icebreaker USCGC Healy transits southbound in the Chukchi Sea during its Arctic deployment on July 5, 2025. The United States Coast Guard icebreaker USCGC Healy transits southbound in the Chukchi Sea during its Arctic deployment on July 5, 2025. Petty Officer 1st Class Steve Strohmaier/U.S. Coast Guard The Newsweek map also shows that the Xue Long 2 remained outside the U.S. Exclusive Economic Zone (EEZ) around Alaska—extending up to 230 miles from the coastline—during its transit, except for a portion of its voyage in the Chukchi Sea prior to reaching the U.S. ECS. What People Are Saying The U.S. Coast Guard wrote in a Facebook post on Monday: "For over 234 years, the American people have relied on the Coast Guard to safeguard our national security, sovereignty, and economic prosperity. Through historic investment in the Coast Guard, we are expanding our icebreaker fleet to ensure American access, security, and leadership in the Arctic." The Chinese Embassy in Washington, D.C., told Newsweek on Tuesday: "China has always conducted normal maritime activities in relevant waters in accordance with international law, including the United Nations Convention on the Law of the Sea. We hope the parties concerned will view this matter in a proper manner, without undue suspicion or groundless speculation." What Happens Next It remains to be seen whether the U.S. will further strengthen its presence in the Arctic amid China's growing activities, with climate change having made the region more accessible.

China's latest childcare subsidy policy is 'just for show', says consultancy
China's latest childcare subsidy policy is 'just for show', says consultancy

CNBC

time31 minutes ago

  • CNBC

China's latest childcare subsidy policy is 'just for show', says consultancy

Sam Radwan, Co-Founder of ENHANCE International, says that the Chinese government is aware that they must appear to be doing something to address the falling birthrate in the country, but it may not be enough. He also says when it comes to the aging population, that China's Ministry of Health has made it crystal clear that the government will only be able to take care of the poor and destitute, and it's looking for the private sector to pick up the slack for the middle and upper class.

Can Low Lupus Activity Predict Outcomes in Lupus Nephritis?
Can Low Lupus Activity Predict Outcomes in Lupus Nephritis?

Medscape

time2 hours ago

  • Medscape

Can Low Lupus Activity Predict Outcomes in Lupus Nephritis?

TOPLINE: Although the lupus low disease activity state (LLDAS) has seldom served as a treatment goal in patients with lupus nephritis, it proved an attainable target and effectively predicted the risk for disease relapse — whether used alone or alongside conventional treatment targets. METHODOLOGY: Researchers analyzed 143 patients with biopsy-proven active lupus nephritis (median age at onset of lupus, 28 years; 92% women) at a tertiary hospital in Hong Kong to assess rates of LLDAS attainment and LLDAS's predictive ability for relapse compared with that of conventional treatment targets. Patients received induction treatment with high-dose glucocorticoids and immunosuppressants, followed by maintenance therapy, and were monitored at least every 4 months for clinical and laboratory assessments. Achievement rates of conventional treatment targets (complete/partial renal response) and LLDAS were assessed at 12 months after the biopsy date. Relapse of lupus nephritis was suspected when proteinuria and/or urinary sediments worsened and/or levels of serum creatinine rose; relapse was confirmed using renal biopsy. Findings were validated in 102 patients (median age at onset of lupus, 30 years; 87% women) from another tertiary hospital in Hong Kong who also attended regular follow-up visits. TAKEAWAY: At 12 months, 40% of 143 patients achieved complete renal response, 10% achieved partial renal response, and 49% achieved LLDAS, indicating that LLDAS is an attainable target comparable to renal response. Patients who achieved neither LLDAS nor complete/partial renal response at 12 months had the highest risk for relapse of lupus nephritis, those who achieved either target had an intermediate risk, and those who achieved both targets had the lowest risk. Further analysis revealed an independent association of achieving complete/partial renal response (hazard ratio [HR], 0.31; P = .007) and LLDAS (HR, 0.38; P = .029) with a reduced risk for disease relapse, with findings validated in the validation cohort as well. Achieving LLDAS also predicted the preservation of renal function, with satisfactory performance in both cohorts (area under the curve, 0.71). IN PRACTICE: 'Our findings demonstrate promise in the potential application of LLDAS as a treatment target and endpoint for future LN [lupus nephritis] trials,' the authors of the study wrote. SOURCE: The study was led by Chak Kwan Cheung, MBBS, Queen Mary Hospital, the University of Hong Kong in Pok Fu Lam, Hong Kong. It was published online on July 20, 2025, in Arthritis Care & Research. LIMITATIONS: The study included only Chinese patients. The 12-month renal response included both complete and partial renal responses, with their individual effects on subsequent renal outcomes not evaluated separately. DISCLOSURES: The study received no financial support. Two authors declared receiving payment or honoraria, support for attending meetings or travelling, having leadership roles, and other ties with certain pharmaceutical companies and organizations. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store